Apimeds Pharmaceuticals US (APUS) Retained Earnings (2023 - 2025)

Apimeds Pharmaceuticals US has reported Retained Earnings for 3 years, with the latest figure at -$10.4 million in Q4 2025.

• For the quarter ending Q4 2025, Retained Earnings fell 136.64% year-over-year to -$10.4 million; the trailing twelve-month figure through Dec 2025 stood at -$10.4 million (down 136.64% YoY), and the FY2025 full-year result was -$10.4 million, down 136.64% from the prior year.
• Retained Earnings for Q4 2025 stood at -$10.4 million, down from -$9.2 million in the prior quarter.
• The five-year high for Retained Earnings was -$3.0 million in Q4 2023, with the low at -$10.4 million in Q4 2025.
• Historically, Retained Earnings has averaged -$6.5 million across 3 years, with a median of -$6.1 million in 2025.
• Annual changes were most pronounced in 2024 — Retained Earnings sank 46.3% — and 2025, when it tumbled 136.64%.
• Apimeds Pharmaceuticals US's Retained Earnings stood at -$3.0 million in 2023, then slumped by 46.3% to -$4.4 million in 2024, then plunged by 136.64% to -$10.4 million in 2025.
• The last three Retained Earnings figures came in at -$10.4 million (Q4 2025), -$9.2 million (Q3 2025), and -$7.5 million (Q2 2025), per Business Quant data.